BCM
AQST icon

Bratton Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Bratton Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.8M Hold
9,810,958
– – 100% 1
2026
Q1 		$40.7M Hold
9,810,958
– – 100% 1
2025
Q4 		$63.4M Hold
9,810,958
– – 100% 1
2025
Q3 		$54.8M Hold
9,810,958
– – 100% 1
2025
Q2 		$32.5M Hold
9,810,958
– – 100% 1
2025
Q1 		$28.5M Hold
9,810,958
– – 100% 1
2024
Q4 		$34.9M Hold
9,810,958
– – 100% 1
2024
Q3 		$48.9M Hold
9,810,958
– – 100% 1
2024
Q2 		$25.5M Hold
9,810,958
– – 100% 1
2024
Q1 		$41.8M Hold
9,810,958
– – 100% 1
2023
Q4 		$19.8M Hold
9,810,958
– – 100% 1
2023
Q3 		$1.5M Hold
9,810,958
– – 100% 1
2023
Q2 		$16.2M Hold
9,810,958
– – 100% 1
2023
Q1 		$11.2M Hold
9,810,958
– – 100% 1
2022
Q4 		$8.85M Hold
9,810,958
– – 100% 1
2022
Q3 		$11.5M Hold
9,810,958
– – 100% 1
2022
Q2 		$6.28M Hold
9,810,958
– – 100% 1
2022
Q1 		$25.6M Hold
9,810,958
– – 100% 1
2021
Q4 		$38.2M Hold
9,810,958
– – 100% 1
2021
Q3 		$42.8M Hold
9,810,958
– – 100% 1
2021
Q2 		$39M Hold
9,810,958
– – 100% 1
2021
Q1 		$51M Sell
9,810,958
-1,692,336
-15% -$9M 100% 1
2020
Q4 		$61.5M Hold
11,503,294
– – 100% 1
2020
Q3 		$55.8M Hold
11,503,294
– – 77.67% 1
2020
Q2 		$55.9M Hold
11,503,294
– – 83.77% 1
2020
Q1 		$25.2M Hold
11,503,294
– – 60.15% 1
2019
Q4 		$66.9M Hold
11,503,294
– – 80.13% 1
2019
Q3 		$36.6M Hold
11,503,294
– – 71.47% 1
2019
Q2 		$48.3M Hold
11,503,294
– – 70.95% 1
2019
Q1 		$79.5M Hold
11,503,294
– – 78.22% 1
2018
Q4 		$72.5M Buy
+11,503,294
New +$145M 75.94% 1

Other funds holding AQST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Bratton Capital Management's AQST Position: Q2 2026 in Review

Bratton Capital Management held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 9,810,958 shares worth $40.8M. The position accounts for 100% of the portfolio, ranked #1.

Bratton Capital Management first reported a position in AQST in Q4 2018 and has held it in 31 quarters since. The position peaked at $79.5M in Q1 2019. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Bratton Capital Management held 9,810,958 shares of Aquestive Therapeutics worth $40.8M as of Q2 2026.
  • Bratton Capital Management left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 100% of Bratton Capital Management's portfolio in Q2 2026, its #1 holding.
  • Bratton Capital Management first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Bratton Capital Management's Aquestive Therapeutics position peaked at $79.5M in Q1 2019.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Bratton Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.